TMCnet News
Research and Markets: Safinamide (Parkinson's Disease) - Forecast and Market Analysis to 2022DUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/76x5rk/safinamide) has announced the addition of the "Safinamide (Parkinson's Disease) - Forecast and Market Analysis to 2022" report to their offering. In 2012, Newron completed Phase III clinical trials for safinamide, a dual-mechanism a-aminoamide derivative, acting as an MAO-B and glutamate release inhibitor (EPDA, press release, May 14, 2012). In 2006, Merck Serono (a division of Merck KGaA) had acquied the exclusive worldwide rights for safinamide; however, in 2011 the deal was terminated, seeing Merck returning the compound to Newron due to concerns over the potential market size for the drug. Scope
Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Safinamide 9 Appendix For more information visit http://www.researchandmarkets.com/research/76x5rk/safinamide
|